Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy
Read MoreNews
- Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
April 08, 2021
- Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
March 29, 2021
- Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2021
- Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
March 09, 2021
Product Pipeline
XEN1101
for Epilepsy
XEN496
for Epilepsy
XEN007
for Orphan Neurological Indications
NBI-921352
for Epilepsy
Partnered with Neurocrine Biosciences
FX301
for Post-Operative Pain
Partnered with Flexion Therapeutics
NAV1.7 Inhibitors
for Pain
Partnered with Genentech
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
